Barclays Elevates Ypsomed, Lowers Gerresheimer as Focus Shifts to Injectable Device Makers
Barclays has reweighted its coverage of European injectable-drug packaging firms, upgrading Ypsomed to overweight with a CHF 343 target while downgrading Gerresheimer to underweight with a €19 target. The move reflects the broker's view that device makers — notably pen and auto-injector suppliers — enjoy higher barriers to switching, better contrac…